Moderna (NASDAQ:MRNA) Releases Earnings Results, Beats Estimates By $1.92 EPS

Moderna (NASDAQ:MRNA) posted its earnings results on Thursday. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92, Briefing.com reports. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the company earned ($1.39) earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis.

Moderna Stock Performance

MRNA stock traded down $3.45 during trading on Friday, hitting $46.83. 13,561,538 shares of the company traded hands, compared to its average volume of 4,882,079. The stock’s 50-day simple moving average is $61.85 and its 200 day simple moving average is $99.22. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The company has a market cap of $18.00 billion, a PE ratio of -3.04 and a beta of 1.69. Moderna has a 1 year low of $46.57 and a 1 year high of $170.47.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,184 shares of company stock worth $238,531. 15.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on MRNA. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Leerink Partners dropped their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Sanford C. Bernstein started coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price target on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a report on Monday, November 4th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $93.18.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.